|20th August 2020||Joseph Walter Vazzano||3,840||Open or private sale||$12.13||$46,579.20|
|14th July 2020||Neil Herskowitz||16,611||Grant/award etc.||$0.00|
|16th June 2020||Jay D Kranzler||10,000||Grant/award etc.||$0.00|
|16th June 2020||Neil Herskowitz||10,000||Grant/award etc.||$0.00|
|5th June 2020||Neil Herskowitz||24,390||Grant/award etc.||$0.00|
|10th March 2020||Joseph Walter Vazzano||1,889||Open or private purchase||$7.94||$14,998.66|
|9th March 2020||Joseph Walter Vazzano||1,400||Open or private purchase||$7.99||$11,186.00|
|9th March 2020||Joseph Walter Vazzano||100||Open or private purchase||$7.97||$797.00|
|27th February 2020||Neil Herskowitz||2,400||Open or private purchase||$8.20||$19,680.00|
|26th February 2020||Neil Herskowitz||161||Open or private purchase||$8.73||$1,405.53|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded in 2015 and is headquartered in New York, NY.